A number of stocks fell in the morning session after the Trump administration's announcement of new global tariffs reignited ...

Life sciences tools company Agilent Technologies (NYSE:A) will be reporting earnings this Wednesday afternoon. Here’s what you need to know.

CE-IVD certification puts Ella in focus for Bio-Techne investors Bio-Techne (TECH) just secured CE-IVD marking for its Ella benchtop immunoassay platform in the European Union, opening the door for ...

Healthcare services company Sotera Health (NASDAQ:) will be reporting earnings this Tuesday before market open. Here’s what ...

Bio-Techne's Ella platform achieves CE-IVD marking expanding access to rapid, cartridge-based immunoassays for European clinical labs: Minneapolis Tuesday, February 17, 2026, 14:0 ...

The global growth factors market is growing steadily, expected to be valued at approximately US$2.5 billion in 2026 and ...

In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Australian Broker Call *Extra* Edition, featuring additional sources of ...

The global growth factors market is growing steadily, expected to be valued at approximately US$2.5 billion in 2026 and projected to reach US$3.7 billion ...

The rising prevalence of various infectious diseases, such as malaria, leishmaniasis, and HIV-AIDS, globally is directly propelling the demand for ELISpot and fluoroSport assays. Cancer also covers a ...

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my ...

NEW YORK — Bio-Techne said on Monday that its Ella benchtop immunoassay platform has received CE-IVD marking, permitting its sale in the EU.

Techne's Ella ELISA platform to run its ovarian cancer test, advancing toward FDA 510(k) filing and supply deal.